Capricor Therapeutics (CAPR) Profit After Tax (2010 - 2026)

Capricor Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$33.9 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 39.15% year-over-year to -$33.9 million; the TTM figure through Mar 2026 stood at -$114.6 million (down 108.11% YoY), while the FY2025 annual figure was -$105.0 million, down 159.58% from the prior year.
• Profit After Tax was -$33.9 million for Q1 2026 at Capricor Therapeutics, down from -$30.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$762089.0 in Q4 2023 to a low of -$33.9 million in Q1 2026.
• Historically, Profit After Tax has averaged -$13.6 million across 5 years, with a median of -$7.8 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax jumped 90.13% in 2023, then plunged 833.83% in 2024.
• A 5-year view of Profit After Tax shows it stood at -$7.7 million in 2022, then surged by 90.13% to -$762089.0 in 2023, then slumped by 833.83% to -$7.1 million in 2024, then tumbled by 323.95% to -$30.2 million in 2025, then retreated by 12.5% to -$33.9 million in 2026.
• The last three Profit After Tax figures came in at -$33.9 million (Q1 2026), -$30.2 million (Q4 2025), and -$24.6 million (Q3 2025), per Business Quant data.